Prognostic value of plasma secretoneurin concentration in patients with heart failure with reduced ejection fraction in one-year follow-up

References

• Plášek J, Lazárová M, Dodulík J, et al. Secretoneurin as a novel biomarker of cardiovascular episodes: are we there yet? A narrative review. J Clin Med. 2022;11(23):1. doi:10.3390/jcm11237191.
   Web of Science ®Google Scholar
• Brynildsen J, Myhre PL, Lyngbakken MN, et al. Circulating secretoneurin concentrations in patients with moderate to severe aortic stenosis. Clin Biochem. 2019a;71:17–11. doi:10.1016/j.clinbiochem.2019.06.008.
   PubMed Web of Science ®Google Scholar
• Brynildsen J, Petäjä L, Myhre PL, et al. Circulating secretoneurin concentrations after cardiac surgery: data from the FINNish acute kidney injury heart study. Crit Care Med. 2019b;47(5):e412–e419. doi:10.1097/CCM.0000000000003670.
   PubMed Web of Science ®Google Scholar
• Myhre PL, Ottesen AH, Faaren AL, et al. Performance of a novel research-use-Only secretoneurin ELISA in ­patients with suspected acute coronary syndrome: comparison with an established secretoneurin radioimmunoassay. Cardiology. 2021;146(5):566–574. doi:10.1159/000517444.
   PubMed Web of Science ®Google Scholar
• Ottesen AH, Carlson CR, Eken OS, et al. Secretoneurin is an endogenous calcium/Calmodulin-Dependent protein kinase II inhibitor that attenuates Ca2+-dependent arrhythmia. Circ Arrhythm Electrophysiol. 2019;12(4):e007045. doi:10.1161/CIRCEP.118.007045.
   PubMed Web of Science ®Google Scholar
• Ottesen AH, Louch WE, Carlson CR, et al. Secretoneurin is a novel prognostic cardiovascular biomarker associated with cardiomyocyte calcium handling. J Am Coll Cardiol. 2015;65(4):339–351. doi:10.1016/j.jacc.2014.10.065.
   PubMed Web of Science ®Google Scholar
• Røsjø H, Stridsberg M, Ottesen AH, et al. Prognostic value of secretoneurin in critically ill patients with infections. Crit Care Med. 2016;44(10):1882–1890. doi:10.1097/CCM.0000000000001832.
   PubMed Web of Science ®Google Scholar
• Watanabe T. The emerging roles of chromogranins and derived polypeptides in atherosclerosis, diabetes, and coronary heart disease. Int J Mol Sci. 2021;22(11):6118. doi:10.3390/ijms22116118.
   PubMed Web of Science ®Google Scholar
• Banach J, Grochowska M, Gackowska L, et al. Melanoma cell adhesion molecule as an emerging biomarker with prognostic significance in systolic heart failure. Biomark Med. 2016;10(7):733–742. doi:10.2217/bmm-2016-0053.
   PubMed Web of Science ®Google Scholar
• Banach J, Wołowiec Ł, Rogowicz D, et al. Procalcitonin (PCT) predicts worse outcome in patients with chronic heart failure with reduced ejection fraction (HFrEF). Dis Markers. 2018;2018:9542784–9542786. doi:10.1155/2018/9542784.
   PubMed Web of Science ®Google Scholar
• Grześk G, Witczyńska A, Węglarz M, et al. Soluble guanylyl cyclase activators-promising therapeutic ­option in the pharmacotherapy of heart failure and pulmonary hypertension. Molecules. 2023;28(2):861. doi:10.3390/molecules28020861.
   PubMed Web of Science ®Google Scholar
• Kennedy SG, Gaggin HK. Leveraging biomarkers for precision medicine in heart failure. J Card Fail. 2023;29(4):459–462. doi:10.1016/j.cardfail.2023.03.001.
   PubMed Web of Science ®Google Scholar
• Rogowicz D, et al. Usefulness of serum high-sensitivity C-reactive protein (hs-CRP) level as prognostic factor in patients with chronic heart failure. J Educ Health Sport. 2016;6(7):513–524. doi:10.5281/zenodo.58867.
   Google Scholar
• Snelder SM, Pouw N, Aga Y, et al. Biomarker profiles in obesity patients and their relation to cardiac dysfunction. Biomark Med. 2021;15(14):1211–1221. doi:10.2217/bmm-2021-0101.
   PubMed Web of Science ®Google Scholar
• Wołowiec Ł, Rogowicz D, Banach J, et al. Catestatin as a new prognostic marker in stable patients with heart failure with reduced ejection fraction in two-year follow-up. Dis Markers. 2020;2020:8847211–8847210. doi:10.1155/2020/8847211.
   PubMed Web of Science ®Google Scholar
• Wołowiec Ł, Rogowicz D, Banach J, et al. Prognostic significance of red cell distribution width and other red cell parameters in patients with chronic heart failure during two years of follow-up. Kardiol Pol. 2016;74(7):657–664. doi:10.5603/KP.a2016.0004.
   PubMed Web of Science ®Google Scholar
• Woźniak-Wiśniewska A, Błażejewski J, Bujak R, et al. The value of cancer antigen 125 (Ca 125) and copeptin. Folia Cardiologica. 2017;12(6):537–542. doi:10.5603/FC.2017.0103.
   Google Scholar
• Aakre KM, Ottesen AH, Strand H, et al. Biological variation of secretoneurin; a novel cardiovascular biomarker implicated in arrhythmogenesis. Clin Biochem. 2021;98:74–77. doi:10.1016/j.clinbiochem.2021.09.014.
   PubMed Web of Science ®Google Scholar
• Mitchell K, Mikwar M, Da Fonte D, et al. Secretoneurin is a secretogranin-2 derived hormonal peptide in vertebrate neuroendocrine systems. Gen Comp Endocrinol. 2020;299:113588. doi:10.1016/j.ygcen.2020.113588.
   PubMed Web of Science ®Google Scholar
• Chan CK, Vanhoutte PM. Secretoneurin facilitates endothelium-dependent relaxations in porcine coronary arteries. Am J Physiol Heart Circ Physiol. 2011;300(4):H1159–65. doi:10.1152/ajpheart.00519.2010.
   PubMed Web of Science ®Google Scholar
• Nowaczyk A, Kowalska M, Nowaczyk J, et al. Carbon monoxide and nitric oxide as examples of the youngest class of transmitters. Int J Mol Sci. 2021;22(11):6029. doi:10.3390/ijms22116029.
   PubMed Web of Science ®Google Scholar
• Yan S, Wang X, Chai H, et al. Secretoneurin increases monolayer permeability in human coronary artery ­endothelial cells. Surgery. 2006;140(2):243–251. doi:10.1016/j.surg.2006.04.001.
   PubMed Web of Science ®Google Scholar
• Kirchmair R, Gander R, Egger M, et al. The neuropeptide secretoneurin acts as a direct angiogenic cytokine in vitro and in vivo. Circulation. 2004;109(6):777–783. doi:10.1161/01.CIR.0000112574.07422.C1.
   PubMed Web of Science ®Google Scholar
• Kähler CM, Schratzberger P, Kaufmann G, et al. Transendothelial migration of leukocytes and signalling mechanisms in response to the neuropeptide secretoneurin. Regul Pept. 2002;105(1):35–46. doi:10.1016/s0167-0115(01)00379-2.
   PubMedGoogle Scholar
• Albrecht-Schgoer K, Schgoer W, Holfeld J, et al. The angiogenic factor secretoneurin induces coronary angiogenesis in a model of myocardial infarction by stimulation of vascular endothelial growth factor signaling in endothelial cells. Circulation. 2012;126(21):2491–2501. doi:10.1161/CIRCULATIONAHA.111.076950.
   PubMed Web of Science ®Google Scholar
• Chen H-L, Liu Y, Jiang W, et al. Secretoneurin suppresses cardiac hypertrophy through suppression of oxidant stress. Eur J Pharmacol. 2018;822:13–24. doi:10.1016/j.ejphar.2018.01.008.
   PubMed Web of Science ®Google Scholar
• Røsjø H, Stridsberg M, Florholmen G, et al. Secretogranin II; a protein increased in the myocardium and circulation in heart failure with cardioprotective properties. PLoS One. 2012;7(5):e37401. doi:10.1371/journal.pone.0037401.
   PubMed Web of Science ®Google Scholar
• Escobar C, Barrios V. SGLT 2 inhibitors: searching for the best in class. Int J Cardiol. 2023;384(23):48–49. doi:10.1016/j.ijcard.2023.04.025.
   PubMedGoogle Scholar
• Grześk G, Dorota B, Wołowiec Ł, et al. Safety of PCSK9 inhibitors. Biomed Pharmacother. 2022b;156:113957. doi:10.1016/j.biopha.2022.113957.
   PubMed Web of Science ®Google Scholar
• Grześk G, Wołowiec Ł, Rogowicz D, et al. The importance of pharmacokinetics, pharmacodynamic and repetitive use of levosimendan. Biomed Pharma­cother. 2022a;153:113391. doi:10.1016/j.biopha.2022.113391.
   PubMed Web of Science ®Google Scholar
• Grześk G, Woźniak-Wiśniewska A, Błażejewski J, et al. The interactions of nintedanib and oral anticoagulants-molecular mechanisms and clinical implications. Int J Mol Sci. 2020;22(1):282. doi:10.3390/ijms22010282.
   PubMed Web of Science ®Google Scholar
• Mustroph J, Neef S, Maier LS. CaMKII as a target for arrhythmia suppression. Pharmacol Ther. 2017;176:22–31. doi:10.1016/j.pharmthera.2016.10.006.
   PubMed Web of Science ®Google Scholar
• Pellicena P, Schulman H. CaMKII inhibitors: from research tools to therapeutic agents. Front Pharmacol. 2014;5:21. PMID: 24600394; PMCID: PMC3929941. doi:10.3389/fphar.2014.00021.
   PubMed Web of Science ®Google Scholar